Read + Write + Report
Home | Start a blog | About Orble | FAQ | Sites | Writers | Advertise | My Orble | Login

BIOPHARMICA SCREENING YIELDS 43 CANCER DRUG LEADS

June 30th 2008 09:32
Friday June 27, 2008

Daily news on ASX-listed biotechnology companies

* ASX, BIOTECHS DOWN: SUNSHINE HEART UP 14%, OPTISCAN DOWN 10%

* BIOPHARMICA HLS5 SCREENING YIELDS 43 NEW CANCER DRUG LEADS

* NEW INTERSUISSE BIOTECH FUND TAKES 4.3% OF SUNSHINE HEART

* PSIVIDA EARLY MEDIDUR FA DATA SHOWS EFFICACY, SAFETY

* AVEXA NEEDS AN APRICITIBINE PARTNER BY SEPTEMBER

* FMR, FIDELITY DROPS 3% OF COCHLEAR IN JUNE

* NOVOGEN’S MARSHALL EDWARDS ON RUSSELL 3000 INDEX

* EASTLAND MEDICAL TAKES 90% OF STAR MEDICAL

* SIRTEX APPOINTS DARREN SMITH INTERIM CFO


subscribe to Biotech Daily at the link above or at www.biotechdaily.com.au

BIOPHARMICA

Biopharmica says the researchers at the Western Australian Institute for Medical Research who discovered the HLS5 gene have found 43 potential anti-cancer molecules.

Biopharmica says the Western Australian Institute for Medical Research (WAIMR) scientists have shown that increased expression of the HLS5 gene in human cancer cells can profoundly suppress tumor growth and they have found that HLS5 interacts with a number of proteins which control cell growth and maturation.

Biopharmica said a screening program of 70,000 synthetic compounds that can modulate HLS5 activity, “yielding 43 molecules that demonstrate potential for further anti-tumor analyses and drug development”.

The company said the evaluation of the growth-inhibitory activity and therapeutic potential of these molecules was being pursued at WAIMR in conjunction with other leading specialist research facilities in Australia.

Biopharmica said research results indicated that nearly half of the compounds can suppress the growth of human cancer cells.

Further, by computer modeling it has been determined that nearly all of these growth-inhibitory molecules demonstrate drug-like qualities and are therefore highly suitable candidates for pharmaceutical development.

Biopharmica intends to progress this drug pipeline toward pre-clinical testing of anti-cancer activity.

Biopharmica was up half a cent or 14.29 percent to four cents.

subscribe to Biotech Daily at the link above or at www.biotechdaily.com.au



18
Vote
Shared on
Add To: del.icio.us Digg Furl Spurl.net StumbleUpon Yahoo


   
Subscribe to this blog 


Just this blog This blog and DailyOrble (recommended)

   

   

   




Add A Comment

To create a fully formatted comment please click here.


CLICK HERE TO LOGIN | CLICK HERE TO REGISTER

Name or Orble Tag
Home Page (optional)
Comments
Bold Italic Underline Strikethrough Separator Left Center Right Separator Quote Insert Link Insert Email
Notify me of replies
Notify extra people about this comment
Is this a private comment?
List the Email Addresses or Orble Tags of the people you would like to be notified about this comment


One per line max of 30

List the Email Addresses or Orble Tags of the people you would like to be notified about this private comment thread. Only the people in this list will be able to see or reply to your comment.


One per line max of 30

Your Name
(for the email going out to the above list, it can be different to your Orble Tag)
Your Email Address
(optional)
(required for reply notification)
Submit
More Posts
6 Posts
24 Posts
18 Posts
322 Posts dating from August 2006
Email Subscription
Receive e-mail notifications of new posts on this blog:
0

Biotech Daily Editor's Blogs

I have no other blogs :(
Copyright © 2006 2007 2008 On Topic Media PTY LTD. All Rights Reserved. Design by Vimu.com.
On Topic Media ZPages: Sydney |  Melbourne |  Brisbane |  London |  Birmingham |  Leeds     [ Advertise ] [ Contact Us ] [ Privacy Policy ]